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CD157, amember of theCD38 gene family, is anNAD-metab-
olizing ectoenzyme and a signaling molecule whose role in
polarization, migration, and diapedesis of human granulocytes
has been documented; however, themolecular events underpin-
ning this role remain to be elucidated. This study focused on the
role exerted by CD157 in monocyte migration across the endo-
thelial lining and adhesion to extracellular matrix proteins. The
results demonstrated that anti-CD157 antibodies block mono-
cyte transmigration and adhesion to fibronectin and fibrinogen
but thatCD157 cross-linking is sufficient to overcome theblock,
suggesting an active signaling role for the molecule. Consistent
with this is the observation that CD157 is prevalently located
within the detergent-resistant membrane microdomains to
which, uponclustering, it promotes the recruitment of1 and2
integrin, which, in turn, leads to the formation of a multimo-
lecular complex favoring signal transduction. This functional
cross-talk with integrins allows CD157 to act as a receptor
despite its intrinsic structural inability to do so on its own. Intra-
cellular signals mediated by CD157 rely on the integrin/Src/
FAK (focal adhesion kinase) pathway, resulting in increased
activity of the MAPK/ERK1/2 and the PI3K/Akt downstream
signaling pathways, which are crucial in the control ofmonocyte
transendothelialmigration. Collectively, these findings indicate
that CD157 acts as a molecular organizer of signaling-compe-
tent membrane microdomains and that it forms part of a larger
molecular machine ruled by integrins. The CD157-integrin
partnership provides optimal adhesion and transmigration of
human monocytes.
Ectoenzymes include a heterogeneous group of surface mol-
ecules with multiple functions. In addition to interacting with
specific substrates, many of them participate in leukocyte acti-
vation and migration. In some cases, ectoenzymes exert enzy-
matic control of leukocyte trafficking (1). Other functions are
independent of their enzymatic ability, relying on the activation
of signaling cascades that lead to calcium fluxes, cytoskeletal
remodeling, and release of inflammatory mediators (2, 3). In
selected cases, ectoenzymes associate with adhesion molecules
to regulate their signaling (4, 5).
Along with CD38, human CD157 constitutes the NAD gly-
cohydrolase/ADP-ribosyl cyclase gene family (6). These two
molecules share 36% of their protein sequence, including 10
cysteine residues forming intrachain disulfide bonds. However,
they differ in structure, with CD157 being a glycosylphosphati-
dylinositol (GPI)5-anchored glycoprotein and CD38 being a
transmembrane type II glycoprotein (7). CD157 is mainly
expressed by cells of the myeloid lineage, bone marrow stroma,
and vascular endothelium (8). CD157 is also expressed by ovar-
ian cancer epithelium and by peritoneal mesothelial cells,
where it is implicated in tumor dissemination (9). Further, it is
endowed with receptor-like features observed in different cell
types (10) and transduces signals by interacting with trans-
membrane partner molecules (11, 12), a strategy shared by
other GPI-anchored molecules (13).
CD157 is involved in neutrophil polarization, adhesion, and
motility (11) and controls transendothelial migration (14). This
study extends the analysis of the functional role of CD157 to
human monocytes, adopted as a physiological model in which
to explore the molecular mechanism underlying the role of the
molecule in the control of cell motility.
Monocytes play key functions in innate and adaptive immu-
nity, immune surveillance, host defense, and inflammation
(15). Furthermore, monocyte trafficking is a critical factor in
inflammatory and autoimmune diseases, such as atherosclero-
sis, multiple sclerosis, and rheumatoid arthritis (16).
Monocytes originate from hematopoietic precursors in the
bone marrow and circulate in the blood for 24–48 h before
extravasating into the connective tissues. In inflammation,
monocytes are recruited to the affected tissues, where they dif-
ferentiate into macrophages and dendritic cells (17). The con-
tinuous traffic from blood to tissue and from tissue to lymph
nodes relies on orchestrated sequential interactions between
leukocytes and vascular or lymphatic endothelium (18). Each
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step is a prerequisite for the next one. Cell adhesion molecules
(such as selectins and integrins) have well established roles in
supporting tethering, rolling, and firm adhesion to the vascular
endothelium (19). Chemokines and selected molecules at the
endothelial junctions (including CD31, JAM-1, vascular endo-
thelial cadherin, and CD99) are critical in the control of the
transmigration process (20). These central components are
flanked by an increasing number of molecules from different
families, which contribute to distinct steps of the extravasation
cascade (21).
The results obtained in this study indicate that CD157 is
involved in the control ofmonocyte extravasation and adhesion
to ECM proteins. CD157 establishes a structural interaction
with 1 and 2 integrin and, following antibody-induced cross-
linking, it promotes their relocation into detergent-resistant
domains, thus driving the dynamic reorganization of signaling-
competent membranemicrodomains. Moreover, CD157 effec-
tively contributes to the integrin-driven signaling network that
is critical during monocyte transmigration.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—The anti-CD157 (SY/11B5, IgG1),
anti-1 integrin/CD29 (Moon-4, IgG1), anti-CD71 (CB26,
IgG2a) mAb, and irrelevant murine monoclonal IgG (mIgG1)
were produced in-house. Anti-CD11b (107, IgG1) and anti-2
integrin/CD18 (TS1/18, IgG1) mAbs were provided by A. Arn-
out (Harvard Medical School, Boston, MA). All mAbs were
affinity-purified on protein G, and the F(ab)2 fragments were
obtained using immobilized papain (Sigma-Aldrich). RF3 (anti-
CD157, IgG2a) mAb was fromMBL International, D01P (anti-
CD157 polyclonal IgG) was from Abnova, 3H1192 (anti-CD29,
IgG2a) mAb was from Santa Cruz Biotechnologies, and anti-
actin was from Sigma-Aldrich. Selected mAbs were coupled to
Alexa Fluor 488 (Molecular Probes) or Chromis-550 (Cyana-
gen) according to themanufacturer’s instructions. The affinity-
purified, F(ab)2 fraction of rabbit antibodies to mouse IgG
(F(ab)2 RMIgG), F(ab)2 RMIgG labeled with FITC (F(ab)2
RMIgG-FITC), and streptavidin-Dylight-549 were from
Jackson ImmunoResearch Laboratories. Fibronectin (FN),
fibrinogen, crystal violet, and FITC or horseradish peroxidase
(HRP)-labeled cholera toxin -subunit (Ctx) were from Sigma-
Aldrich. Monocyte chemoattractant protein-1 (MCP-1),
TNF, and IL-1 were from Peprotech.
Cells and Cell Lines—Peripheral blood mononuclear cells
were isolated from healthy blood donors by density gradient
centrifugation, after informed written consent. Monocyte neg-
ative selection was performed via magnetic activated cell sort-
ing using the monocyte isolation kit (Miltenyi Biotec) accord-
ing to the manufacturer’s instructions. This yielded 95%
monocytes, as determined by flow cytometry following labeling
with anti-CD14-FITC mAb (BD Biosciences).
Human monocytic THP-1 cell line (ATCC, Manassas, VA)
was maintained in RPMI 1640 medium supplemented with 5%
FCS. The human pulmonary microvascular endothelial cells
(HPMEC) were generated as described (22).
Flow Cytometry—Cells (2 105/sample) were incubated for
30 min at 4 °C with 5 g/ml of appropriate primary mAbs,
washed, and incubated for 30 min at 4 °C with F(ab)2 RMIg-
FITC. Fluorescence was determined using a FACSCalibur flow
cytometer and analyzed with CellQuest software (BD Biosci-
ences). Background mAb binding was estimated by means of
isotype-matched negative control mAb. Ten thousand events
were considered for each analysis.
Transendothelial Migration Assay—HPMEC were grown to
confluence on 5-m pore Transwell chambers (Corning-Co-
star) coated with fibronectin (10 g/ml) and either left
unstimulated or stimulated for 4 h at 37 °C with TNF (20
ng/ml) or IL-1 (10 units/ml). Peripheral blood mononuclear
cells (5 105) were treatedwith the indicatedmAbs (10g/ml)
for 20 min before the assay and then seeded on the HPMEC
monolayers. To induce CD157 cross-linking, F(ab)2 RMIgG
(50 g/ml) was added to the desired samples. After a 2-h incu-
bation at 37 °C, the transmigrated (suspended and adhered)
monocytes were collected and counted by FACS at medium
speed for 3 min. The transmigration index (TMI) was deter-
mined using the formula: TMI (number of cells migrated in
the presence of blockingmAb)/(number of cellsmigrated in the
presence of mIgG).
Cell Adhesion to ECM Proteins—Purified monocytes or
THP-1 cells (5 104) pretreated with selectedmAbs (10g/ml
for 20 min) were plated onto 96-well plates coated with FN (10
g/ml) or fibrinogen (50 g/ml) and blocked with 2% BSA. To
induce CD157 cross-linking, F(ab)2 RMIgG (50 g/ml) was
added to the indicated samples. After a 1-h incubation at 37 °C,
non-adherent cells were removed by washing, and adherent
cells were fixed with 4% paraformaldehyde and stained with
0.5% crystal violet. Adherent cells were assessed by light
microscopy, and five randomly selected fields (10) for each
well were photographed and counted. Each condition was car-
ried out in quadruplicate, and experiments were repeated at
least three times.
Isolation of Detergent-insoluble Microdomains (Lipid Rafts)
by Sucrose Gradient Centrifugation and Western Blot Analysis—
THP-1 cells (5 107) were lysed in 0.7 ml of ice-coldMES lysis
buffer (25 mM MES, pH 6.5, 5 mM NaF, 1 mM Na3VO4, 2 mM
EDTA, 150 mM NaCl, 0.5% Triton X-100, 50 g/ml aprotinin,
and leupeptin). Where indicated, cells were pretreated (10 min
at 37 °C) with FN (10 g/ml), with anti-CD157 mAb (5 g/ml),
or with anti-CD157 mAb followed by F(ab)2 RMIgG (20
g/ml for 1 min at 37 °C). Cell lysates were mixed (v/v) with
80% sucrose (w/v in MES buffer), and a step gradient was pre-
pared by overlaying with 30 and 5% sucrose/MES. After centri-
fugation at 200,000  g for 16 h at 4 °C, 12 fractions (0.4
ml/each) were collected starting from the top of the gradient.
Equal amounts of each fraction were resolved on 10% SDS-
PAGE under non-reducing conditions, transferred to polyvi-
nylidene difluoride (PVDF) membranes, and subjected to
Western blotting with the indicated mAbs followed by
RMIgG-HRP and then developed using an ECL-based system
(PerkinElmer Life Sciences). The lipid raft marker GM1 was
detected by dot blot analysis using HRP-labeled Ctx.
Immunofluorescence and Confocal Microscopy—Serum-
starved cells were fixed in Hanks’ balanced salt solution (pH
6.5) containing 2% paraformaldehyde and 1 mM ZnCl2 for 20
min, washed twice in Hanks’ balanced salt solution, and treated
for 30 min with 50 mM glycine in Hanks’ balanced salt solution
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supplementedwith 1%FCS to quench the aldehyde groups (23).
Fixed cells were double-stainedwith anti-CD157-Chromis-550
and anti-CD18- or CD29-Alexa Fluor 488 mAbs or Ctx-FITC.
In selected experiments, cells were incubatedwith anti-CD157-
biotin (5 g/ml for 10 min on ice), washed, and reacted with
streptavidin-Dylight-549 (20g/ml for 10min on ice) and then
placed at 37 °C for 2min to induce capping, blocked by ice-cold
PBS with 0.5% BSA and 0.1% NaN3, and fixed as above. Coun-
terstaining was performed with anti-CD18-, CD29-, or CD71-
Alexa Fluor 488 mAbs or Ctx-FITC. Engagement of integrins
was induced by incubating THP-1 cells (5 106/ml) in Hanks’
balanced salt solution with FN (10 g/ml) at 37 °C for 10 min.
Cells were fixed, stainedwith the indicatedmAbs, and analyzed
by confocal microscopy, using an Olympus FV300 laser scan-
ning confocal microscope equipped with two helium neon (543
and 582 nm) lasers, a blue argon (488 nm) laser, and FluoView
300 software (Olympus Biosystems). Cells were imaged using a
60 oil immersion objective (1.4 NA). Images of optical sec-
tions (512 512 pixels) were digitally recorded and processed
using Adobe Photoshop CS4 (Mountain View, CA) software.
For co-localization analysis, all image data were preprocessed
prior to quantification bymeans of an iterative constrainedTik-
honov-Miller algorithm (DeconvolutionLab ImageJ plugin
(24)) to reduce the blurring from nearby bright objects and the
out-of-focus noise. Co-localization was evaluated using the
Colocalization Colormap script, an ImageJ plugin for auto-
mated quantification and visualization of co-localized fluores-
cent signals (25). The method computes correlation of intensi-
ties between pairs of individual pixels in two different channels.
Results are presented as mean correlation index (Icorr) S.E.
Icorr indicates the fraction of positively correlated pixels in the
image.
Co-immunoprecipitation Assays—THP-1 cells were treated
with 0.5 mM membrane-impermeable cross-linker dithiobis
sulfosuccinimidylpropionate (Pierce) for 30 min at 20 °C. The
reactionwas stoppedwith 20mMTris for 15min, and then cells
were washed and lysed in ice-coldMES buffer. Cell lysates were
centrifuged at 14,000 g for 30min, precleared overnight with
protein G-Sepharose beads, and then incubated overnight at
4 °C with protein G-Sepharose beads conjugated to 2 g of
anti-CD157, anti-CD18, anti-CD29, or anti-CD71 mAbs. The
beads were washed with PBS, and proteins were eluted by add-
ing non-reducing Laemmli sample buffer and boiling for 5min.
Eluted proteins were resolved on 10% SDS-PAGE under non-
reducing conditions, transferred to PVDF membranes, and
probed with mAbs to CD157, CD18, CD29, or CD71 followed
by HRP-conjugated secondary antibodies and then detected
using ECL.
PhosphorylationAssay—THP-1 cells (2 107/ml) were incu-
bated with anti-CD157, anti-CD18, and anti-CD29 mAb (5
g/ml) for 10min at 4 °C,washed in cold PBS, cross-linkedwith
F(ab)2 RMIgG (20 g/ml), and incubated at 37 °C for 1 min.
Cells were placed on ice, washed in cold PBS supplemented
with 1 mM Na3VO4 to stop the reaction, and lysed in ice-cold
radioimmune precipitation buffer (50 mM Tris HCl, 150 mM
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM
EDTA, 0.1% SDS supplementedwith 1mMNa3VO4, 5mMNaF,
50 g/ml aprotinin and leupeptin). After centrifugation, total
lysates (30 g/lane) were run on 10% SDS-PAGE under
reducing conditions and transferred to PVDF membranes.
Membranes were blocked and probed with HRP-labeled
anti-phosphotyrosine (PY20) polyclonal antibody, anti-phos-
pho-ERK1/2 (Tyr-204/Tyr-187) (BD Biosciences), anti-phos-
pho-c-Src (Tyr-530), anti-phospho-FAK (Tyr-397), and anti-
phospho-AKT (Ser-493) (Santa Cruz Biotechnologies). The
membranes were stripped and reprobed with anti-ERK2, anti-
c-Src, anti-FAK, and anti-AKT1 mAb (Santa Cruz Biotechnol-
ogies) followed by incubation with the appropriate HRP-conju-
gated antibodies. Specific bands were visualized by ECL.
Statistical Analysis—Unless otherwise indicated, values are
expressed as means  S.E. Comparisons between two groups
were carried out using the Student’s t test for normal distrib-
uted variables. One-way analysis of variance with Bonferroni
post test correction was used for multiple comparisons. Statis-
tical analyses were performed using Prism 5, GraphPad soft-
ware (San Diego, CA). Differences were considered statistically
significant for p values0.05.
RESULTS
CD157 Expression on Circulating Monocytes Is Up-regulated
by MCP-1—Flow cytometric analysis confirmed that CD157 is
expressed by virtually all the circulating monocytes (Fig. 1A)
and demonstrated that its expression rapidly increases upon
activation withMCP-1, reaching a plateau after 30min of stim-
ulation (Fig. 1, A and B). As expected, CD11b expression was
enhanced byMCP-1 (Fig. 1B) (26). Immunoblot further proved
that CD157 is expressed bymonocytes (data not shown) as well
as the humanmonocytic THP-1 cells at the expectedmolecular
weight (see below, Fig. 5A). Up-regulation ofmonocytic CD157
expression by MCP-1, a chemoattractant factor that promotes
monocyte migration and diapedesis, suggested the potential
involvement of CD157 in monocyte trafficking.
CD157 Is Involved in Monocyte Transendothelial Migration—
A central aspect of leukocyte trafficking is the continuous tran-
sition from the blood circulation into the tissues and back. The
vascular endothelium constitutes the interface between the two
tissue compartments, so transendothelial migration represents
a critical step of leukocyte trafficking.
The potential role ofCD157 in regulating transmigrationwas
explored in a conventional in vitro assay using primary mono-
cytes treated with a blocking anti-CD157 mAb or with an anti-
CD31 mAb used as a positive control for blocking transmigra-
tion (27). To avoid interfering with the Fc receptors expressed
bymonocytes, F(ab)2mAbswere used. Because themajority of
leukocyte traffic occurs in vivo primarily through themicroves-
sels, we usedHPMEC asmonolayers to reproduce amore phys-
iological environment. These experiments were initially done
with resting HPMEC monolayers across which monocytes
migrate in response to basal concentrations of chemoattrac-
tants, such as MCP-1 (28). The results demonstrated that
CD157 ligation by a specific mAb resulted in significant inhibi-
tion of transmigration of monocytes, comparable with that
obtained with a blockingmAb to CD31. Anti-CD157-mediated
inhibition was dose-dependent with significant effects down to
0.4 g/ml (Fig. 1C).
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In concert with neutrophils, monocytes and tissue macro-
phages participate in inflammatory responses. Therefore, the
role of CD157 in transendothelial migration was investigated
using cytokine-activated HPMEC monolayers, thereby simu-
lating an inflammatory microenvironment. Stimulation with
TNF or IL-1 had no effect on the surface expression or dis-
tribution of CD157 on endothelial cells (14). Ligation of CD157
with a specificmAb significantly reduced transmigration across
TNF-activated HPMEC (Fig. 1D) or across IL-1-activated
HPMEC (data not shown). Tomimic the extent of CD157 clus-
tering likely occurring on monocytes during transmigration,
monocytes were treatedwith anti-CD157mAb, and then cross-
linking of CD157 was induced by the addition of F(ab)2
RMIgG prior to their addition to the HPMECmonolayer (t
0). Alternatively, monocytes treated with anti-CD157 mAb
were seeded on HPMEC monolayers for 30 min (a sufficient
time for monocytes to get to endothelial junctions), and then
CD157 cross-linking was performed. Antibody-induced clus-
tering of CD157 overcome the block and significantly restored
monocyte transmigration. The effect was independent of the
timing of cross-linking (Fig. 1D). Antibody-induced cross-link-
ing of CD31 at the start of the assay (t 0) failed to reverse the
blockade, whereas it was effective when performed at t  30
min (Fig. 1D), as described (29). These data gave raise to the
hypothesis that clustering of CD157 might function as a switch
that controls transmigration by eliciting intracellular signaling.
CD157 Controls Monocyte Adhesion to Extracellular Matrix
Proteins—Adhesion of leukocytes to the extracellular matrix is
essential for migration across blood vessels and subsequently
into the stroma of inflamed tissues (30). It is regulated by a wide
variety of cell surface receptor systems, the most relevant of
which belong to the 1 and 2 integrin subfamilies.
The contribution of CD157 in regulating the adhesion of
monocytes to fibronectin and fibrinogen (i.e. the elective extra-
cellular ligands of 1 and 2 integrin, respectively) was assessed
by performing in vitro experiments using monocytes or THP-1
cells treated with anti-CD157 mAbs. Ligation of CD157 signif-
icantly reduced the ability of monocytes (Fig. 2, A and B) and
THP-1 cells (Fig. 2C) to adhere to both ECM proteins. As
expected, cell binding to fibrinogen and fibronectin was inhib-
ited by neutralizing antibodies to CD29 (1 integrin) (Fig. 2, A
andC) andCD18 (2 integrin)(Fig. 2B), respectively. Combined
FIGURE 1. CD157 is expressed in humanmonocytes and is involved in transendothelial migration. A, representative flow cytometric analysis of surface
expression of CD157 onmonocytes (black peak) or onmonocytes stimulatedwithMCP-1 for 30min (white peak). The gray peak indicates the isotype-matched
control mAb. Ten thousand events were considered for each analysis. The results presented are representative of three experiments. x axis fluorescence
intensity (FL-1-height), and y axis number of cells (events). B, monocytes were treatedwith 10MMCP-1 for the indicated time at 37 °C, fixed, and incubated
with anti-CD157 or anti-CD11bmAb followed by F(ab)2 RMIgG-FITC. Results showing the increasing rate ofmean fluorescence intensity (MFI) are expressed
as MCP-1-induced expression of CD157/basal or of CD11b/basal surface expression of each molecule at 37 °C. The results are expressed as means of three
separate experiments  S.E. C, transmigration assays across resting HPMEC grown on fibronectin-coated Transwell filters were performed toward a 10 M
MCP-1 Transwell gradient in the presence of increasing concentrations of F(ab)2 anti-CD157 (black bars), anti-CD31 mAb (gray bar), or mIgG (white bar) (10
g/ml). After a 2-h incubation at 37 °C, the number of transmigratedmonocyteswas assessed by FACS atmedium speed for 3min. Results are themean S.E.
of three separate experiments and are expressed as TMI. Anti-CD157 blocked transmigration in a dose-dependent manner. **, p 0.01 and ***, p 0.001. D,
cross-linkingmonocyteCD157 reverses the anti-CD157-inducedblock in transmigration.Monocytespretreatedwith F(ab)2 anti-CD157 (black bars), anti-CD31
mAb (gray bars), or mIgG (white bars) (10 g/ml) were added to HPMECmonolayers activated with TNF- (20 ng/ml) for 2 h at 37 °C. Where indicated, CD157
andCD31were cross-linked (at time0or30minafter thebeginningof the transmigration)by theadditionof aF(ab)2 RMIgG (50g/ml). After a2-h incubation
at 37 °C, transmigrated monocytes were counted as above. Results are expressed as TMI and are the mean  S.D. of three replicates. One representative
experiment of five is shown. **, p 0.01 and ***, p 0.001.
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ligation of CD157 andCD29 or CD157 andCD18 resulted in an
increased inhibition on both monocyte and THP-1 cell adhe-
sion. However, none of the experimental conditions analyzed
entirely abrogated cell adhesion, indicating that other mole-
cules must also participate. Strikingly, CD157 clustering
induced by cross-linking with a secondary antibody reversed
the blockade and virtually completely restored monocyte (Fig.
3, A and B) and THP-1 cell (Fig. 3C) adhesion. Taken together,
these data suggested the existence of a functional interplay
between CD157 and both 1 and 2 integrin orchestrating crit-
ical steps of leukocyte trafficking and corroborate the hypoth-
esis that CD157 is involved in intracellular signal transduction.
CD157Engagement Recruits1 and2 Integrins toDetergent-
resistant (Lipid Raft) Domains—Next, the possibility that
CD157 was engaged in the transduction of activation signals
regulating monocyte functions was investigated. The GPI-me-
diated anchorage to the membrane, indicating the lack of a
transmembrane domain of CD157, fostered the hypothesis that
it could fulfill receptor functions in the context of membrane
microdomains, as part of multimolecular complexes. To
address this issue, THP-1 cells (used as amonocytemodel)were
subjected to lysis and discontinuous sucrose gradient centrifu-
gation to separate detergent-resistant (lipid rafts) from deter-
gent-sensitive (non-rafts) membrane fractions. To validate the
fractionation procedure, Ctx was used to identify ganglioside
GM1, a major constituent of lipid rafts, whereas CD71 (a raft-
excluded protein) was chosen as a marker of the detergent-
sensitive fractions. In standard culture conditions and like
many other GPI-anchored molecules (31), CD157 almost
exclusively associated to detergent-insoluble fractions. A sub-
stantial portion of both 1 (CD29) and 2 (CD18) integrins was
found outside the detergent-insoluble fractions (Fig. 3A).
When THP-1 cells were treated with anti-CD157 mAb, which
can cross-link two CD157 molecules, the membrane compart-
mentalization of CD157, CD18, and CD29 was similar to that
observed in untreated cells (Fig. 3B). To exclude that the
observed membrane compartmentalization of CD157 and
integrins represented an artifact of detergent extraction, con-
focal microscopy analysis was performed in parallel on live
THP-1 cells. This approach showed that CD157 had a charac-
teristic patched pattern in basal conditions and largely co-local-
ized with GM1 gangliosides. In contrast, CD18 and CD29 were
uniformly localized on the cell membrane (Fig. 4, A and D, left,
and E).
To establish whether cross-linking of many CD157 mole-
cules accompanied the reorganization of the membrane topol-
ogy, the distribution of CD157, CD18, and CD29 molecules on
the cell membrane was monitored after CD157 clustering,
using biochemical approaches and confocal microscopy.
FIGURE 2. Effect of CD157 on the adhesion of monocytes to fibrinogen
and fibronectin. A–C, monocytes (A and B) or THP-1 cells (C) were treated
with the indicated mAbs (10 g/ml for 20 min). CD157 cross-linking was
induced by the addition of F(ab)2 RMIgG (50g/ml for 20min) where indi-
cated. Cells were plated onto 96-well plates coatedwith FN or fibrinogen and
incubated for 1 h at 37 °C, and then washed, fixed, and stained with crystal
violet. The number of monocytes that had adhered to ECM proteins was
counted in five randomly selected fields in each well. Results represent the
mean  S.E. of three experiments performed in quadruplicate. **, p  0.01
and ***, p 0.001.
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CD157 cross-linking by means of a mAb followed by the
addition of a secondary antibody triggered the recruitment
into the raft fractions of significant amounts of CD18 and
CD29 (Fig. 3C). Confocal microscopy analysis on live cells
confirmed these results. CD157 molecules were induced to
cap by mAb cross-linking at 37 °C, and the membrane fluid-
ity and energy intake (required to induce clustering of mol-
ecules) were blocked by incubation of the cells on ice in the
presence of NaN3 and successive fixation. Upon primary and
secondary antibody binding, CD157 molecules and the area
of the cell membrane with the highest concentration of GM1
gangliosides localized at the same pole of the cell membrane
(Fig. 4B, bottom). Co-capping experiments highlighted that
polar aggregation of CD157 induced CD18 and CD29 to
localize in identical areas of the membrane in the majority of
cells (Fig. 4, B and D,middle, and E). These results indicated
that CD157 clustering in human monocytes led 1 and 2
integrins into the rafts.
Increasing evidence suggests that ligand-induced oligomeri-
zation causes the activation of integrins and provides the stim-
ulus for their associationwith rafts (32, 33). It was reasonable to
expect that ligand-induced integrin oligomerization would
cause their lateral association with CD157. To test this hypoth-
esis, clustering of integrins was induced by incubating THP-1
cells with fibronectin. As anticipated, integrin engagement by
fibronectin shifted a significant fraction of both CD18 and
CD29 from the non-raft to the raft compartment (Fig. 3D).
Next, the effects of interaction with fibronectin on integrin
compartmentalization into lipid rafts were examined by confo-
cal microscopy. Capping of CD29 and CD18 induced by THP-1
incubation with fibronectin was accompanied by co-localiza-
tion with CD157 (Fig. 4, C and D, right) in 84 and 74% of the
cells, respectively (Fig. 4E). No co-localization of CD157 with
CD71 was observed in any of the experimental conditions
adopted (Fig. 4, D and E). Together, these results confirmed
that CD157 and integrins are interdependent partners in a
functional biological network.
CD157 Is Physically Associated with 1 and 2 Integrins on
Monocyte Membrane—The observation that cross-linking of
CD157 induced co-localization of 1 and 2 integrins in the
same areas on the membrane of THP-1 cells suggested that
they might be physically associated. To test this hypothesis,
we performed co-immunoprecipitation experiments. The
results showed that the anti-CD157 mAb recognized its
45-kDa target protein in the anti-CD18 as well as in the
anti-CD29 eluates. Reciprocally, anti-CD29 and anti-CD18
mAb were able to react with the expected 130- and 95-kDa
bands, respectively, in the anti-CD157 mAb eluates. How-
ever, the anti-CD71 mAb failed to recognize its target pro-
tein in any of the eluates; reciprocally, anti-CD157, anti-
CD18, and anti-CD29 mAbs failed to react with their target
proteins in the anti-CD71 eluates, demonstrating specificity
(Fig. 5A). These results indicated that, as we demonstrated in
granulocytes (12), CD157 is likewise physically bound to
both 1 and 2 integrin at the cell surface of human mono-
cytes. These observations strongly support the hypothesis of
functional cross-talk between CD157 and integrins instru-
mental to the control of monocyte transmigration.
CD157 Exerts Receptor Activities in Human Myeloid Cells—
Topographic relocation of activated receptors, including integ-
rins, into lipid rafts provides foci of intracellular signaling for
the cell and may be considered a general mechanism that guar-
antees leukocyte functions. Therefore, molecules (such as
CD157) that promote raft association are likely to effectively
FIGURE 3. CD157 engagement recruits1 and2 integrins to lipid rafts. A–D, THP-1 cells untreated (A), treatedwith F(ab)2 anti-CD157mAb (5g/ml) (B),
treatedwith F(ab)2 anti-CD157mAb (5g/ml) followed by F(ab)2 RMIgG (20g/ml for 1min at 37 °C) (C) or treatedwith fibronectin (10g/ml for 10min at
37 °C) to induce cross-linking (D) were lysed in coldMES buffer and fractionated on a sucrose gradient as described under ”Experimental Procedures.“ Aliquots
of the 12 recovered fractions were resolved on 10% SDS-PAGE and immunoblotted with mAb to CD157, CD18, and CD29 followed by RMIgG-HRP. Localiza-
tionof theGM1ganglioside (detectedbyCtx-HRP) andofCD71was checkedbydotblot analysis as a control of theproper separationof thedetergent-resistant
(rafts 3–7) and detergent-sensitive (non-rafts 8–12) fractions, respectively. One representative experiment of four is shown.WB, Western blot.
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contribute to the transduction of intracellular signals that trig-
ger the effector functions.
Further insights into signaling events driven by CD157 in
monocytic cells were gathered by exploring the phosphoryla-
tion pathway induced on THP-1 cells through antibody-medi-
ated cross-linking. Experiments were performed in parallel
using anti-CD18 and anti-CD29mAbs.Western blot analysis of
the proteins tyrosine phosphorylated after short term stimula-
tion at 37 °C demonstrated that CD157 clustering induced a
rapid and transient increase of phosphorylation of a broad
range of molecules, largely shared with the target substrates of
CD18- and/or CD29-mediated activation pathways (Fig. 5B).
The increase in phosphorylation reached a peak at 1 min and
persisted for 5 min, declining thereafter (data not shown).
The most relevant bands featuring increased intensity as com-
pared with the basal condition (i.e. cells treated with F(ab)2
RMIgG for 1min at 37 °C) were at 130, 110, 65, 44, and 42 kDa
(as indicated by arrows) (Fig. 5B). Western blot analysis per-
formed using substrate-specific antibodies indicated that target
substrates included FAK (p130), c-Src (p65), the serine/threo-
nine kinase Akt (a key downstream effector of p110 phospho-
inositide 3-kinase), and MAPK ERK1/2 (p42–44) (Fig. 5C).
FIGURE4.Confocalmicroscopy andquantitative analysis of co-localization of CD157 andCD18or CD157 andCD29 in live cells.A, THP-1 cells were
stained with anti-CD157-Chromis-550 (red), fixed, and stained with anti-CD18-Alexa Fluor 488 (green) or anti-CD29-Alexa Fluor 488 mAbs or Ctx-FITC. B,
THP-1 cells were stained with anti-CD157-biotin mAb followed by streptavidin-Dylight-549 (red) at 4 °C and then moved to 37 °C for 2 min to induce
capping. After fixation, cells were stained with anti-CD18-Alexa Fluor 488 or anti-CD29-Alexa Fluor 488 mAbs or Ctx-FITC. C, THP-1 cells were treated
with fibronectin (10 g/ml for 10 min at 37 °C) and then fixed and stained with anti-CD157-Chromis-550 and anti-CD18-Alexa Fluor 488 or anti-CD29-
Alexa Fluor 488 mAbs or Ctx-FITC. Cells were mounted onto slides and imaged using a confocal scanning laser microscope (FV300) mounted on an IX71
invertedmicroscope (Olympus, Hamburg, Germany) with a PlanApo60 oil immersion objective, 1.4 numerical aperture (NA) objective lens. Images are
from a single focal plain scan of the Z stacks. The results of one representative experiment of three are shown. Scale bar: 10 m. D, co-localization of
CD157 and Ctx, CD157 and CD18, CD157 and CD29, or CD157 and CD71 in THP-1 cells unstimulated (left), activated by CD157 cross-link (middle), or
activated by FN (right) was quantified in 60–80 cells in each sample using the Colocalization Colormap script ImageJ plugin for automated quantifica-
tion and visualization of co-localized fluorescent signals. Histograms represent the mean correlation index (Icorr) S.E. of Chromis-550/Alexa Fluor 488
(or FITC) or Dylight-549/Alexa Fluor 488. E, the percentage  S.D. of THP-1 cells showing co-localization of the indicated molecules in the indicated
experimental conditions.
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CD157 is a GPI-anchored molecule with no intrinsic signal-
ing capacity; it has been hypothesized that the molecule estab-
lishes physical association with transmembrane receptors to
transduce signals. The structural association between CD157
and both 1 and 2 integrin and the coexistence of CD157 with
selected integrins in specific membrane domains provided the
rationale for identifying integrins as likely candidates for being
CD157 partner proteins. Evidence was sought by inducing
combined clustering ofCD157 and1 integrin orCD157 and2
integrin on the plasma membrane of THP-1 cells by means of
antibody cross-linking. The results showed that concurrent
ligation of CD157with either CD18 orCD29 is accompanied by
a sharp increase in phosphorylation of c-Src, Akt, and ERK1/2,
with no variations in the absolute amount of c-Src, Akt, and
ERK1/2 in the cell lysates (Fig. 5, B–D). These results indicated
that CD157 can use both 1 and 2 integrins as tools in signal
transduction. This leads to the activation of distinct down-
stream signaling pathways converging on the MEK/ERK path-
way, which is responsible for controlling crucial aspects of
monocyte extravasation.
FIGURE 5. CD157 interacts with integrins and induces intracellular signal transduction after cross-linking. A, THP-1 cells lysates were immunoprecipi-
tated (IP) with the indicated mAbs. Proteins were eluted, resolved on 10% SDS-PAGE, and analyzed by Western blotting (WB) using anti-CD157, anti-CD18,
anti-CD29, or anti-CD71 mAbs. Western blotting was performed three times, and a representative example is presented. B, THP-1 cells were incubated with
F(ab)2 anti-CD157, CD18, andCD29mAb (5g/ml) followedby F(ab)2 RMIgG (20g/ml for 10min at 4 °C and 1min at 37 °C) and lysed. To induce combined
engagement of CD157 and CD18 or CD157 and CD29 on plasmamembrane, THP-1 cells were simultaneously incubated with the indicated primarymAbs (10
min at 4 °C) followed by F(ab)2 RMIgG. Total lysates (30 g/lane) were resolved on 10% SDS-PAGE, immunoblotted, and probed with HRP-labeled anti-
phosphotyrosine antibody. C, THP-1 cells were incubated with the indicated primary mAb followed by F(ab)2 RMIgG. Immunoblots were probed with
anti-phospho-FAK (p-FAK), anti-phospho-c-Src (p-cSrc), anti-phospho-AKT (p-AKT), or anti-phospho-ERK1/2 antibody (p-ERK1/2). -Actin was used as loading
control. The membranes were stripped and reprobed with anti-FAK, anti-c-Src, anti-AKT, and anti-ERK2 antibodies detecting the total form of each protein
followed by incubationwith the appropriate HRP-conjugated antibodies. One representative experiment of three is shown.D, the increased phosphorylation
of c-Src (left), Akt (middle), and ERK2 (right) induced by CD157 cross-linking on THP-1 cells was quantified and compared with that induced by combined
cross-linking of either CD157 plus CD18 or CD157 plus CD29. Images were scanned using an image scanner and quantitatively analyzed using the software
package NIH ImageJ 1.43 (National Institutes of Health, Bethesda, MD). Results are means  S.E. of three separate experiments and are expressed as -fold
increase in phosphorylation as comparedwith that obtainedby treating cellswith the F(ab)2 RMIgGalone (20g/ml, basal phosphorylation 1). *,p 0.05,
**, p 0.01, and ***, p 0.001. A.U., arbitrary units.
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Monocyte recruitment to extravascular sites is an important
component of the inflammatory response to a variety of stimuli
such as bacterial infections, tumor growth, and atherosclerotic
plaque formation. The surface expression and release (as solu-
ble proteins or membrane vesicles) (34) of a number of mole-
cules serves to coordinate and fine-tune the local inflammatory
response according to the particular circumstances. Here we
present evidence that CD157 is one of these molecules. We
used antibody-mediated cross-linking of CD157 to mimic its
natural clustering (a strategy commonly adopted for initiating
signal transduction, although the actualmechanism of how this
works remains unclear) and demonstrated that CD157 cross-
linking promotes1 and2 integrin relocation and orchestrates
the assembly of signaling-competent membrane domains. The
outcome is regulation of monocyte behavior. This unique role
of CD157 accounts for its involvement in critical functions of
monocytes, including (i) transendothelial migration and (ii)
adhesion to ECM proteins. CD157 operates both in non-in-
flammatory as well as in inflammatory conditions. Indeed, the
extent of the inhibitory effects of blocking mAb on transmigra-
tion across quiescent and activated endothelium is comparable.
However, forced clustering of CD157 through the addition of a
secondary cross-linking antibody at the beginning of or during
the process is sufficient to significantly restore transmigration,
suggesting that CD157 cross-linking triggers signal transduc-
tion. The results obtained in adhesion assays strengthened this
assumption. Indeed, clustering of CD157 by the addition of a
secondary cross-linking antibody to mouse IgG was able to
revert the blockade induced by the anti-CD157mAb. The orig-
inally described enzymatic functions of CD157 and CD38 (the
othermember of theNAD glycohydrolase/ADP-ribosyl cyclase
gene family) have progressively givenway to a burgeoning array
of functions in activation signaling (35, 36) and lateral associa-
tionswithmultiple partnermolecules on the plasmamembrane
(36–38).
We demonstrated that antibody-induced CD157 aggrega-
tion can elicit rapid intracellular Ca2 mobilization and pro-
mote neutrophil polarization. The efficiency of these effects is
proportional to the extent of cross-linking, suggesting that the
aggregation of many molecules is crucial to the formation of
competent signalingmicrodomains (11). In alignment with this
observation, here we demonstrated that anti-CD157 mAb,
which can cross-link two molecules, is not sufficient to drag
integrins into rafts and, consequently, to transduce activation
signals; hence, it blocks transmigration and adhesion, likely
preventing leukocyte interaction with a so far unidentified
physiological ligand(s). Furtherworkwill be required to unravel
the actual molecular mechanism by which the antibody block-
ade of CD157 interferes with monocyte transmigration and
adhesion to ECM proteins.
CD157 is bound to the cell membrane by a GPI anchor. This
means that it has no access to the cytoplasmic face of the plasma
membrane and therefore lacks direct contact with intracellular
signaling intermediates. Although the mechanisms underlying
signal transduction through GPI-anchored proteins are not
fully understood, an accepted model is that these molecules
create complexes with membrane-spanning proteins, which
then act as a signal transduction device. Here we demonstrated
that in human monocytes, CD157 forms a multimolecular
complex with integrins. Indeed, according to the co-immuno-
precipitation experiments, it is physically bound to CD18 and
CD29; furthermore, it functionally interacts with both integ-
rins, as highlighted by adhesion assays.
GPI-anchored proteins are generally concentrated in lipid
rafts, which are microdomains within the plasma membrane
enriched with glycosphingolipids, cholesterol, and several sig-
naling elements (39). Lipid rafts are thought to provide the
milieu necessary for bringing discrete receptors and down-
stream intermediates into close proximity, thereby allowing the
formation of signaling-competent microdomains. Our data
showed that (i) CD157 is virtually entirely located within the
lipid rafts on the THP-1 cell membrane and (ii) CD157 cluster-
ing causes CD18 and CD29 integrins to accumulate in the lipid
rafts, much in the sameway as with selected ECMproteins (40).
Activated 1 and 2 integrins, but not inactive molecules,
were reported as preferentially localized in lipid rafts in lym-
phocytes (41). The recruitment of integrins into lipid rafts was
postulated as being a mechanism regulating their activity (42).
The affinity for lipid rafts is an inherent feature of integrins as it
is shared by integrins activated in several ways (43). Conceiv-
ably, in addition to the interaction with their ligand, integrins
could be held within the lipid rafts as a result of their lateral
association with membrane proteins residing within them (44,
45). Our results demonstrate that this is the case for CD157 on
monocytes. Indeed, following CD157 aggregation, a consider-
able amount of both CD18 and CD29 moves to the lipid raft
compartment of the cell membrane, resulting in subsequent
activation of downstream signaling. The ability to form large
raft patches with signaling activity following cross-linking is a
feature shared by GPI-anchored molecules (46); instead, the
promotion of integrin compartmentalization into lipid rafts is
not a prerogative of all GPI-anchored molecules. For example,
CD87 cross-linking on myeloid cells is unable to promote 2
integrin redistribution into lipid rafts (47). The existence of
physical interactions between CD157 and integrins provides a
compelling basis formotivating their functional interplay; how-
ever, the molecular bases supporting the structural interaction
of CD157 with different integrins remain unclear and deserve
further investigation. These findings indicate that CD157 (i)
behaves as a molecular organizer of membrane microdomains
and (ii) is part of the integrin-driven molecular machinery that
regulates crucial functions of monocytes, including transendo-
thelial migration and adhesion to ECM proteins.
To explore the signal transduction cascade raised by CD157
engagement, we assessed the phosphorylation status of selected
proteins upon CD157 antibody cross-linking and demon-
strated that CD157-mediated intracellular signaling relies on
integrin/Src/FAK, leading to increased activity of downstream
MAPK/ERK1/2 and PI3K/Akt pathways. These pathways are
core components of the integrin-mediated signaling network
coordinating complex biological responses of monocytes, such
as cell growth, adhesion, and migration, in normal and patho-
logical conditions (48).
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In this dynamic interplay between CD157 and integrins, not
only doesCD157 share effector targetswith1 and2 integrins,
which represent crucial checkpoints of leukocyte trafficking,
but it also acts as a stimulatory molecule and cooperates with
both integrins in the control of cell migration and adhesion.
Indeed, concurrent engagement of CD157 and integrins
resulted in increased tyrosine kinase receptor phosphorylation
and PI3K and MAPK signaling cascade activation. This is con-
sistent with previous reports demonstrating the need to aggre-
gate integrins on monocyte plasma membrane to achieve max-
imal tyrosine phosphorylation leading to optimal effector
functions (49, 50).
It is easy to imagine that in a physiological context, CD157
engagement by its non-substrate ligand (so far unknown)
recruits pre-existing 1 and 2 integrin nanoclusters (50) into
lipid rafts, thus influencing their three-dimensional organiza-
tion and promoting the transduction of intracellular signals,
which drive efficient cytoskeletal rearrangements, cell adhe-
sion, and transmigration. These conclusions are further sup-
ported by the observation that neutrophils from patients
with paroxysmal nocturnal hemoglobinuria (which express
neither CD157 nor other GPI-anchored molecules as a result
of an acquired genetic mutation) (51) are characterized by
defective transendothelial migration and adhesion to ECM
proteins (11, 14).
It is tempting to speculate that the spatial reorganization
induced in vitro by mAb cross-linking is a general mechanism
implemented in vivo by the interaction between CD157 and its
ligand to offer cells (leukocytes or ovarian tumor cells (9)) with
privileged areas for optimal response to the outside environ-
ment. The identification of a non-substrate ligand of CD157 is
expected to shed light on these issues.6
In conclusion, these results begin to outline a model where
CD157 controls leukocyte extravasation through relocation of
integrins into signaling-competent microdomains (i.e. signalo-
somes), which are required to efficiently recruit protein tyro-
sine kinases and scaffolding proteins and to switch on the com-
plex network of interconnected signaling pathways (21, 52).
Integrins are attractive targets for the treatment of inflam-
matory and autoimmune diseases, and several specific antibod-
ies have been tested in clinical trials. However, the integrin-
blocking approaches have significant side effects related to
impaired host response (53). The existence of CD157 as an
integrin-associated molecule that mediates specific functions
offers the potential for fine-tuning integrin functions and per-
mitting the development of improved therapeutic strategies in
inflammatory diseases such as arthritis and atherosclerosis.
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